Improved delivery of Mcl-1 and survivin siRNA combination in breast cancer cells with additive siRNA complexes [0.03%]
利用增强的siRNA复合物在乳腺癌细胞中更有效地传递Mcl-1和survivin组合siRNA（ additive siRNA）
Tinnabhop Santadkha,Wanwisa Skolpap,Remant K C et al.
Tinnabhop Santadkha et al.
This study aimed at investigating the influence of commercial transfection reagents (Prime-Fect, Leu-Fect A, and Leu-Fect C) complexed with different siRNAs (CDC20, HSP90, Mcl-1 and Survivin) in MDA-MB-436 breast cancer cells and the impact...
Real-world data on efficacy and safety of azacitidine therapy in chronic myelomonocytic leukemia in China: results from a multicenter, retrospective study [0.03%]
中国去甲基化药物地西他滨治疗慢性粒单细胞白血病真实世界疗效和安全性分析——一项多中心回顾性研究结果
Yu Xu,Rong Guo,Miao Miao et al.
Yu Xu et al.
Chronic myelomonocytic leukemia (CMML) is a rare and aggressive myeloid malignancy with overlapped features of myelodysplastic syndromes/myeloproliferative neoplasms. Azacitidine (AZA), a hypomethylating agent, has been approved for the tre...
Multicenter Study
Investigational new drugs. 2022 Oct;40(5):1117-1124. DOI:10.1007/s10637-022-01283-x 2022
First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors [0.03%]
一种新型的强力双胍类氧化磷酸化(OXPHOS)抑制剂IM156治疗晚期实体瘤患者的首个人体研究
Filip Janku,Seung-Hoon Beom,Yong Wha Moon et al.
Filip Janku et al.
Preclinical models suggest anticancer activity of IM156, a novel biguanide mitochondrial protein complex 1 inhibitor of oxidative phosphorylation (OXPHOS). This first-in-human dose-escalation study enrolled patients with refractory advanced...
Brain pharmacokinetics and metabolism of the AMP-activated protein kinase selective inhibitor SBI-0206965, an investigational agent for the treatment of glioblastoma [0.03%]
SBI-0206965的脑药代动力学和代谢：一种治疗胶质母细胞瘤的试验药物
Janki M Desai,Aniruddha S Karve,Gary A Gudelsky et al.
Janki M Desai et al.
Purpose: Emerging evidence suggests that 5' Adenosine Monophosphate-Activated Protein Kinase (AMPK), a key regulator of cellular bioenergetics, is a novel target for the treatment of glioblastoma (GBM), a lethal brain tum...
3D cell cultures, as a surrogate for animal models, enhance the diagnostic value of preclinical in vitro investigations by adding information on the tumour microenvironment: a comparative study of new dual-mode HDAC inhibitors [0.03%]
三维细胞培养物作为一种动物模型替代品，通过添加有关肿瘤微环境的信息增强了临床前体外研究的诊断价值：新型双模式HDAC抑制剂的比较研究
Sofia I Bär,Bernhard Biersack,Rainer Schobert
Sofia I Bär
Anchorage-independent 3D-cultures of multicellular tumour spheroids (MCTS) and in vitro microtumours of cancer cells can provide upfront information on the effects of anticancer drug candidates, tantamount to that obtained from animal xenog...
Two novel piperidones induce apoptosis and antiproliferative effects on human prostate and lymphoma cancer cell lines [0.03%]
两种新型哌啶酮诱导人前列腺和淋巴瘤癌症细胞系凋亡及抗增殖作用
Risa Mia Swain,Lisett Contreras,Armando Varela-Ramirez et al.
Risa Mia Swain et al.
Cancer remains the second most common cause of death in the US. Due to a recurrent problem with anticancer drug resistance, there is a current need for anticancer drugs with distinct modes of action for combination drug therapy We have test...
Combination of TACE and Lenvatinib as a promising option for downstaging to surgery of initially unresectable intrahepatic cholangiocarcinoma [0.03%]
TACE联合仑伐替尼作为初始不可切除的肝内胆管癌降级手术的一项颇具前景的选择
Peng Yuan,Jinhua Song,Fei Wang et al.
Peng Yuan et al.
Background: Conversion therapy has been widely applied in various cancer types including intrahepatic cholangiocarcinoma (ICC). The aim of this retrospective study was to evaluate the efficacy and safety of transarterial ...
Author Correction: The 45-month therapy outcomes of permanent seed implantation and radical prostatectomy for prostate cancer patients [0.03%]
作者更正：永久性种子植入和根治性前列腺切除术治疗前列腺癌患者的45个月疗效
Chao Li,Mengdong Zhang,Jianwen Wang et al.
Chao Li et al.
Published Erratum
Investigational new drugs. 2022 Oct;40(5):1164. DOI:10.1007/s10637-022-01273-z 2022
Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study [0.03%]
安罗替尼联合依托泊苷和顺铂/卡铂作为广泛期小细胞肺癌一线治疗的II期、单臂研究
Tiandong Kong,Lu Chen,Xiaoli Zhao et al.
Tiandong Kong et al.
Patients with extensive-stage small-cell lung cancer (ES-SCLC) have high relapse rates and poor prognosis. Anlotinib monotherapy has shown promising efficacy for patients with ES-SCLC and has a non-overlapping toxicity profile with chemothe...
Phase I study of aflibercept in combination with docetaxel in Japanese patients with advanced solid malignancies [0.03%]
阿柏西普联合多西他赛治疗日本晚期实体瘤患者I期临床研究
Yu Sunakawa,Keishiro Takahashi,Osamu Kawaguchi et al.
Yu Sunakawa et al.
Angiogenesis is a hallmark of cancer development. This study sought to determine the recommended dose of aflibercept, a recombinant fusion protein targeting VEGF-A, VEGF-B and placental growth factor (PlGF), combined with docetaxel in Japan...